Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen, has struck a fresh biosimilars deal with Biogen that will give the firm marketing rights to two of Samsung Bioepis’ biosimilar candidates, ranibizumab and aflibercept, that are currently in pre-clinical and clinical development.
The agreement offers Biogen commercialization rights to the SB11 ranibizumab and SB15 aflibercept candidates in the US, Canada, Europe, Japan...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
